Abstract
Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Betacoronavirus / isolation & purification
-
COVID-19
-
COVID-19 Drug Treatment
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / virology
-
Female
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Ivermectin / therapeutic use*
-
Male
-
Middle Aged
-
Nasopharynx / virology
-
Pandemics
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / virology
-
Retrospective Studies
-
SARS-CoV-2
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Immunosuppressive Agents
-
Ivermectin
-
tocilizumab
Grants and funding
The authors received no specific funding for this work.